Table 12.
Comparison between MAPS indirect atrophy rate and MAPS-HBSI. Three subjects were excluded from the indirect atrophy rate comparison due to missing SNT volumes at 12-month follow-up (2 MCI subjects (031_S_0568 and 002_S_0954) and 1 AD subject (141_S_0852)). Three subjects were excluded from the correlation analysis because: the baseline AVLT score of 1 AD subject (099_S_0372) was -1 in Trial V, the 12-month repeat AVLT scores of 1 AD subject (073_S_0565) were all -1 in Trials I-V and the 12-month repeat AVLT scores of 1 MCI subject (067_S_0607) were -1 in Trials IV and V.
| MAPS indirect atrophy rate | MAPS-HBSI | MAPS indirect atrophy rate vs MAPS-HBSI | ||
|---|---|---|---|---|
| Mean (SD) atrophy rate, % | Differences in mean (95% CI) | SD ratio (95% CI) | ||
| Controls (n=98) | 1.40 (3.11) | 1.15 (2.02) | 0.25 (-0.19 to 0.69), p=0.13 | 1.54 (1.33 to 1.78), p<0.001 |
| MCI (n=141) | 3.68 (3.92) | 2.80 (2.43) | 0.88 (0.38 to 1.37), p<0.001 | 1.61 (1.42 to 1.83), p<0.001 |
| AD (n=61) | 4.57 (3.76) | 4.57 (2.38) | -0.01 (-0.83 to 0.81), p=0.49 | 1.58 (1.27 to 1.97), p<0.001 |
| Sample size (95% CI) | Sample size ratio (95% CI) | |||
| AD rate alone | 170 (99 to 488) | 68 (48 to 99) | 2.51 (1.43 to 5.66), p<0.05 | |
| Controlling for aging | 354 (169 to 1419) | 121 (77 to 206) | 2.92 (1.45 to 8.64), p<0.05 | |
| Sample size (95% CI) | Sample size ratio (95% CI) | |||
| MCI rate alone | 285 (193 to 471) | 189 (139 to 289) | 1.50 (1.09 to 2.21), p<0.05 | |
| Controlling for aging | 742 (367 to 2147) | 545 (296 to 1331) | 1.36 (0.73 to 2.80), p>0.05 | |
| Correlation between atrophy rate and change in AVLT (95% CI) | Differences in correlation (95% CI) | |||
| MCI (n=140) | -0.15 (-0.31 to 0.02) p=0.08 |
-0.22 (-0.38 to -0.06) p=0.008 |
0.07 (-0.03 to 0.18 to 0.03), p=0.18 | |
| AD (n = 59) | 0.13 (-0.13 to 0.37) p=0.33 |
0.04 (-0.22 to 0.20) p=0.77 |
0.09 (-0.23 to 0.41), p=0.58 | |